瑞士生物科技公司Tolremo Therapeutics研发CBP/p300 溴结构域抑制剂，抑制非遗传性癌症产生耐药性

Core Insights - Tolremo Therapeutics is a Swiss biotech company founded in 2017, focusing on the development of CBP/p300 bromodomain inhibitors to combat non-genetic cancer drug resistance [2][4][6] - The company has identified a key mechanism governing transcriptional resistance pathways and developed an oral small molecule inhibitor, TT125-802, which targets CBP/p300 [6][8] - Tolremo has completed a $39 million Series A financing round to accelerate the clinical development of TT125-802, which has shown promising preclinical efficacy in combination with targeted therapies for specific advanced tumors [9] Company Overview - Tolremo Therapeutics is a spin-off from ETH Zurich, founded by Stefanie Flückiger-Mangual, who serves as the CEO [2] - The company aims to reverse non-genetic drug resistance in cancer through targeted transcriptional reprogramming [4][7] Product Development - TT125-802 is designed to block the interaction between CBP/p300 and DNA, preventing early transcriptional escape mechanisms in cancer cells [8] - The inhibitor has demonstrated significant clinical activity in preclinical models of non-small cell lung cancer, colorectal cancer, and prostate cancer when used in combination with existing targeted therapies [8] Clinical Trials and Milestones - In November 2023, Tolremo announced the completion of its first human clinical trial for TT125-802, marking a significant milestone in its development [8] - The company plans to continue clinical trials to evaluate the efficacy of TT125-802 in combination with targeted therapies for specific advanced tumors, including those with EGFR and KRAS mutations [9] Recognition and Innovation - Tolremo Therapeutics was listed in the 2024 TOP100 Swiss Startups, highlighting its status as one of the most innovative and promising companies in Switzerland [11]